Xilio Therapeutics, Inc.XLOEarnings & Financial Report
Nasdaq
XLO Q3 2025 Key Financial Metrics
Revenue
$19.1M
Gross Profit
N/A
Operating Profit
$-1.9M
Net Profit
$-16.3M
Gross Margin
N/A
Operating Margin
-10.1%
Net Margin
-85.4%
YoY Growth
742.5%
EPS
$-0.11
Financial Flow
Xilio Therapeutics, Inc. Q3 2025 Financial Summary
Xilio Therapeutics, Inc. reported revenue of $19.1M for Q3 2025, with a net profit of $-16.3M (-85.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $19.1M |
|---|---|
| Net Profit | $-16.3M |
| Gross Margin | N/A |
| Operating Margin | -10.1% |
| Report Period | Q3 2025 |
Income Statement
| Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.4M | $2.3M | $2.9M | $8.1M | $19.1M |
| YoY Growth | N/A | N/A | N/A | 243.0% | 742.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Assets | $89.9M | $74.7M | $103.7M | $133.8M | $133.7M |
| Liabilities | $56.5M | $53.7M | $93.0M | $126.7M | $141.8M |
| Equity | $33.4M | $21.0M | $10.7M | $7.1M | $-8.1M |
Cash Flow
| Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Operating CF | $20.0M | $-13.7M | $29.0M | $-14.5M | $-17.5M |